Sanjeevan – For Perfect Eyesight develops a technological device called Occlupad for Amblyopia supported by Japan International Cooperation Agency (JICA)

 

The collaboration has helped Sanjeevan to use Occlupad for treating their patients on an ongoing basis. Occlupad is a device created by removing only the polarizing film layer from the liquid crystal display (LCD) screen of an iPad Air, making the LCD screen visible only with the aid of polarizing glasses; otherwise, the screen seems to show a white backlight. Only after wearing the polarizing glasses, the patient can use the device to play games that help in treating their amblyopic eye.

 

At Sanjeevan the treatment provided ameliorates the neural activity in the visual cortex part of the brain that improves the depth perception, binocular vision and three-dimensional vision which are commonly affected in patients with Amblyopia. In addition to this, the treatment provided helps in increasing the blood supply and oxygenation of the retina, which in turn helps in the treatment of Amblyopia.

 

Amblyopia (or lazy eye) is the most common visual disease among children affecting an estimated 2% to 5% of the world population. The primary treatment for amblyopia is patching which many children find difficult. This leads to concerns about treatment compliance. Moreover, there are occlusion therapy risks and side effects such as skin irritation, deprivation amblyopia, and psychological issues associated with the inhibition of binocular function that creates a further cause for concern.

 

Japan International Cooperation Agency (JICA, https://www.jica.go.jp/english/index.html )decided to officially support the collaborative project between Japan and India. The project will be implemented from October 2017 to March 2018.

Speaking on the association with Kitasato University, Dr Rohan Goyal –Director at Sanjeevan – For Perfect Eyesight said, ”Treatment of amblyopia accounts for approximately 90% of visits to children’s’ eye clinics. The Combination of treatment provided by Sanjeevan and Occlupad provides better treatment for patients with positive results thereby creating a whole new treatment avenue which is not practised anywhere in the world. The combined research will yield better results and treatment procedure over eye patching.”

 

Speaking on the collaboration, Dr Tomoya Handa said, “According to our clinical study in Japan, Occlupad is expected to be more than three times more effective than conventional treatment. During the early years of an individual’s life, the visual system develops very rapidly, including the important connections between the brain and the eyes. By beginning training early, the chances for curing amblyopia increase tremendously. This Innovative treatment with Occlupad will help all the children to get the necessary training. This will help achieve great results without the “trauma by eye patching.”  We would like to propose the best treatment results and the best experience for children in the world.

About Sanjeevan

Sanjeevan – For Perfect Eyesight is the brainchild of Dr K. K. Goyal and Mrs Suman Goyal. With a combined experience of more than 45 years, both doctors believe that no ailment of the eye is untreatable. After distilling their veritable experience and through painstaking research, they have devised non-invasive and non-surgical techniques based on proprietary natural therapeutic procedures for most eye disorders.

 

The eye institute has treated patients with various eye ailments, most of which are considered untreatable by allopathic medicine. They vary from Macular Degeneration, Retinitis Pigmentosa, Presbyopia, Amblyopia (Lazy Eyes), Rod-Cone Dystrophies, etc.

 

Sanjeevan For Perfect Eyesight is the only eye care treatment centre in India that possesses the CAD (Color Assessment and Diagnosis) test machine that provides the most comprehensive test for colour blindness in the world. They are also equipped for online consultation. The state-of-the-art eye care facilities are currently at two locations in Mumbai viz Borivali and Chembur.